Liquid Biopsy for Liver Cancer After Y90 Treatment
Part of Cancer, Digestive system clinical trials.
This study uses a simple blood test (called a liquid biopsy) to learn more about your liver cancer after you receive a targeted radiation treatment called Y90 radioembolization. The goal is to see if the blood test can help doctors better understand how the cancer responds to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of liver cancer called HCC, and your cancer is at a stage called BCLC 0, A, B, or C
- A tumor board (a group of liver cancer experts) has approved you for a treatment called Y90 radioembolization
- You have not had surgery or another procedure to remove or destroy the tumor that would be treated with Y90
- You can come to all the follow-up visits your doctor recommends for your care and for this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two liver-directed treatments—radioactive Yttrium-90 beads (SIRT) and a type of chemo infusion directly into the liver (HAIC)—for people whose liver cancer is advanced enough to need treatment but might still be removable with surgery. The goal is to see which approach can shrink the tumor best before surgery.
This study looks at how patients with liver cancer (HCC) respond to a treatment called SIR-Spheres, which are tiny radioactive beads placed in the liver. It is for people who received this treatment in 2023 or early 2024 and were checked for tumor response within six months after treatment.
This study looks at blood tests to see if they can predict how well liver cancer responds to a procedure called TACE. Participation involves giving blood samples and having your normal follow-up scans.
This study tests a targeted radiation treatment called Y90 for liver tumors that are too large for standard approaches. It aims to see how well the treatment works for people with primary or secondary liver cancers that mainly affect the liver and have at least one tumor bigger than 5 cm.
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
This trial tests how well a Y-90 radiation treatment works for liver cancer that hasn't been treated before. It uses ultrasound imaging to check the response.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.